Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial
| Autor: | Jihad Slim, Moupali Das, Shuping Jiang, Aimee M. Wilkin, Andrew T. A. Cheng, Eric Cua, Robert C. Kalayjian, Joseph J. Eron, Cheryl McDonald, Anson K Wurapa, Jeffrey L. Stephens, Sophia Majeed, Stephanie Cox, Brigitte Schmied, Devi SenGupta, Jean-Daniel Lelièvre, Mehri S McKellar |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Epidemiology business.industry Elvitegravir Cobicistat Immunology Emtricitabine 030112 virology Tenofovir alafenamide End stage renal disease 03 medical and health sciences Regimen 0302 clinical medicine Infectious Diseases Virology Internal medicine medicine Outpatient clinic 030212 general & internal medicine Adverse effect business medicine.drug |
| DOI: | 10.17615/m15p-bq49 |
| Popis: | Background: Current treatment for HIV-infected individuals with renal failure on haemodialysis frequently requires complex regimens with multiple pills. A daily single-tablet regimen of coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide is approved in Europe, the USA, and in other regions for use in HIV-1-infected individuals with mild-to-moderate chronic kidney disease (creatinine clearance 30–69 mL/min). We aimed to assess the safety, efficacy, and pharmacokinetics of this regimen in HIV-infected adults with end-stage renal disease on chronic haemodialysis. Methods: We did an open-label, single-arm, multicentre, phase 3b trial at 26 outpatient clinics in Austria, France, Germany, and the USA. Participants were HIV-1-infected adults with end-stage renal disease (creatinine clearance |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|